Singapore, June 23 -- SystImmune and parent company Sichuan Biokin Pharmaceutical have received regulatory approval in China for iza-bren, also known as BL-B01D1, for the treatment of recurrent or metastatic nasopharyngeal carcinoma.

The approval from the Center for Drug Evaluation of China's National Medical Products Administration covers patients whose disease has progressed after prior platinum-based chemotherapy and PD-1 or PD-L1 inhibitor therapy. It marks the first regulatory approval for iza-bren and an important milestone for SystImmune's bispecific antibody-drug conjugate platform.

This is relevant because recurrent or metastatic nasopharyngeal carcinoma remains difficult to treat after standard therapy failure. Although NPC is...